BioArctic

About Us

BioArctic AB is a Swedish research based biopharma company focusing on disease modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. BioArctic focuses on innovative treatments in areas with high unmet medical needs. Collaborations with universities are of great importance to the company together with our strategically important global partners in the Alzheimer (Eisai) and Parkinson (AbbVie) projects. The project portfolio is a combination of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market- and out-licensing potential. BioArctic’s B-share is listed on Nasdaq Stockholm Mid Cap (ticker: BIOA B). For more information about BioArctic, please visit www.bioarctic.com.

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

Interim Report for the period October – December 2024

Thu, Feb 13, 2025 08:00 CET

Pioneering license agreement with BrainTransporter™ signed with BMS worth up to USD 1.35 billion plus royaltiesEvents during the fourth quarter 2024 · The Australian Medicines Agency (TGA) decided not to approve lecanemab. Eisai has requested a reconsideration · The phase 3 study AHEAD 3-45 in preclinical Alzheimer's disease was fully recruited · Eisai completed the stepwise application for subcutaneous maintenance therapy with Leqembi in the US · New data for the BrainTransporter technology was presented, showing a dramatic increase of antibody delivery to the brain ·

There are no items matching the current filter

There are no more items matching the current filter

About Us

Interim Report for the period October – December 2024

Subscribe

Media

Share

About Us

Interim Report for the period October – December 2024

Subscribe

Media